High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer.
Nowhere has there been more controversy in recent years than in the use of high dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation for breast cancer, both in the adjuvant setting and for advanced disease. Authors review and comment on the data from the studies so far reported and try to indicate what will be next in this field. They also discuss what may be the attitude to take in our everyday clinical practice, taking into account the availability of new chemotherapeutic agents and targeted therapies.
Pedrazzoli
P
P
SC Oncologia Medica Falck, Dipartimento Oncologico, Ospedale Niguarda Ca' Granda, 1-20162 Milano, Italy. oncologia@ospedaleniguarda.it
Tarenzi
E
E
Tullio
C
C
Colosini
G
G
Siena
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D009367:Neoplasm Staging; D010865:Pilot Projects; D011379:Prognosis; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome